Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-10-15
2003-03-04
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S937000, C514S938000, C514S944000, C514S943000, C424S451000, C424S457000, C424S464000, C424S468000
Reexamination Certificate
active
06528539
ABSTRACT:
The present invention relates to a stable fumagillin formulation. In particular, the present invention relates to a stable fumagillin formulation for oral or rectal administration.
Fumagillin is an antibiotic which was first described in 1951 (The Merck Index, 12th edition, No. 4308). Originally, fumagillin was used to prevent or combat parasitic diseases in fish farms and apiaries. More recently, fumagillin has been found to be of interest in human therapy. In particular, reference may be made to patent application WO 96/30010 which points out the efficacy of fumagillin in treating intestinal infections caused by microsporidae and/or cryptosporidae especially in patients who have contracted the HIV virus.
Fumagillin, 2,4,6,8-decatetraenedioic acid mono[4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro[2.5]oct-6-yl] ester of formula:
is highly unstable at ambient temperature and must be stored at −80° C. Fumagillin contains many functions that are unstable: unstable at ambient temperature, unstable to light, readily oxidizable or hydrolyzable. Reference may be made to various studies carried out on fumagillin, in particular in: J. Agric. Food Chem. 1991, 39, 2206-2213; J. Pharm. Sci. 1976, 65(1), 1-22; J. Amer. Chem. Soc. 1955, 77, 5610-5617 and J. Amer. Pharm. Ass., Sci. Ed. 1954, 43, 536-543. The various degradations which fumagillin may undergo are thus mainly due to the presence of the epoxy functions, the ester function and the conjugated double bonds. In order for fumagillin to be able to be used as medicinal products, a pharmaceutical formulation which is stable at ambient temperature and easy to store must be prepared.
Certain stable compositions of fumagillol derivatives have already been described.
For example, patent EP 602 586 describes stable pharmaceutical compositions containing a fumagillol derivative and a fatty acid ester of glycerol or of polyglycerol. Patent application EP 799 616 describes pharmaceutical compositions for oral administration comprising a fumagillol derivative and an oleaginous base, said compositions being stable with respect to gastric acid. Neither of these documents specifically describes a fumagillin formulation.
According to the present invention, it is has now been found that in the case of fumagillin, by using a hydrophobic agent: propylene glycol dicaprate/dicaprylate ester, a stable formulation is obtained. A fumagillin formulation which is stable at ambient temperature is thus obtained, without adding a stabilizer or an antioxidant.
The propylene glycol dicaprate/dicaprylate ester, also known as propylene glycol dicaprylocaprate, is sold under the brand name Labrafac® PG.
Thus, the present invention relates to a stable, orally administrable formulation containing fumagillin and propylene glycol dicaprate/dicaprylate.
In particular, the formulation according to the present invention is in the form of a gel capsule or a soft capsule containing fumagillin and propylene glycol dicaprate/dicaprylate. The capsule or gel capsule is preferably non-translucent, for example colored or opaque white. In order to ensure the leaktightness of these formulations, said gel capsules or capsules may be hoop-cased or sealed.
The LEMS (Liquid Encapsulation by Micro Spray) process is carried out continuously directly on leaving the machines for filling the gel capsules (LEMS capsugel). It consists in sealing Licaps gel capsules by a process of pulverization-spraying with aqueous-alcoholic liquid and drying to allow self-bonding of the gelatin between the body and the cap of the gel capsule, thus ensuring the desired leaktightness.
In the conventional hoop casing process, the gel capsules obtained from the filling machines are positioned on a hoop casing machine comprising a gel capsule support belt (the capsules being laid flat in alveolae and in contact with a lower disc. Under the conveyor belt are positioned vertical discs which, by rotating in a gelatin solution, deposit a strip of gelatin between the body and the cap of the gel capsule; where necessary, the gel capsules may be treated twice, that is to say a double hoop casing since, during the first treatment, air microbubbles may be generated in the strip of gelatin deposited. This is a safety operation with regard to the leaktightness.
A formulation in the form of a gel capsule (or capsule) containing a gel capsule (or capsule, respectively) of smaller size containing fumagillin and propylene glycol dicaprate/dicaprylate may also be used.
According to another of its aspects, the present invention relates to drinkable liquid formulations containing a mixture of fumagillin and propylene glycol dicaprate/dicaprylate. These formulations may be in the form of syrup preferably stored in a multidose flask or in the form of a liquid packaged as a single dose ampule. Preferably, the flasks or ampules used are nontranslucent, for example made of brown glass.
A subject of the present invention is also stable, rectally administrable formulations containing fumagillin and propylene glycol dicaprate/dicaprylate. These compositions are preferably packaged in a single dose container with a cannula. The formulations according to the invention advantageously comprise 0.2% to 15% (w/w) and preferably 5% to 12% (w/w) of fumagillin.
The formulations according to the invention may also contain other pharmaceutical excipients. A thixotropic or viscosity-modifying agent may be used in particular, such as, for example, colloidal silica: Aerosil® R972 or Aerosil® R974, or alternatively ethylcellulose, Aerosil® R972 being preferred.
The formulations are prepared as follows: the fumagillin is added to the propylene glycol dicaprate/dicaprylate with gentle stirring in order to homogenize the mixture. The gel capsules are then filled with this mixture by means of a semiautomatic machine.
A subject of the present invention is also the use of these stable fumagillin formulations to prepare medicinal products for treating intestinal infections caused by microsporidae and/or cryptosporidae, and also for treating said infections.
More particularly, the invention relates to the use of these formulations in AIDS patients and for intestinal infections whose main causative agent is the parasite
Enterocytozoon bieneusi.
The daily dose of active principle to be administered naturally varies according to the age and weight of the patient, and also according to the type and severity of the pathology to be treated.
In general, for an adult of normal constitution, the daily dose of active principle to be administered according to the invention is between 1 and 100 mg, preferably between 40 and 80 mg and in particular 60 mg.
The unit forms may contain from 1 to 100 mg of active principle, advantageously from 5 to 50 mg or preferably from 7 to 30 mg, in particular 20 mg. Such unit doses are generally administered 1 to 4 times a day, preferably 3 times a day. This type of treatment lasts from 1 to 4 weeks, preferably 2 weeks.
REFERENCES:
patent: 4918103 (1990-04-01), Park et al.
patent: 5846562 (1998-12-01), Yanai et al.
patent: 5900431 (1999-05-01), Molina et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6316497 (2001-11-01), Liu et al.
patent: 0 602 586 (1994-06-01), None
patent: 0 799 616 (1997-10-01), None
patent: WO 96/30010 (1996-10-01), None
Abramovici Bernard
Dubois Jean-Luc
Alexander Michael D.
Dupont Paul E.
Fay Zohreh
Kwon Brian-Yong S.
Sanofi-Synthelabo
LandOfFree
Stable formulation containing fumagillin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable formulation containing fumagillin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable formulation containing fumagillin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3031188